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Abstract
Purpose Pathological studies suggest that neuroinflammation is
exacerbated by increased beta-amyloid (Aβ) levels in the brain
early in Alzheimer’s disease (AD). The time course and relation-
ships between astrocytosis and Aβ deposition were examined
using multitracer in vivo positron emission tomography (PET)
imaging in an AD transgenic mouse model, followed by post-
mortem autoradiography and immunohistochemistry analysis.
Methods PET imaging with the amyloid plaque tracer 11C-
AZD2184 and the astroglial tracer 11C-deuterium-L-deprenyl
(11C-DED) was carried out in APPswe mice aged 6, 8–15 and
18–24months (4–6 animals/group) and in wild-type (wt) mice
aged 8–15 and 18–24 months (3–6 animals/group). Tracer
uptake was quantified by region of interest analysis using
PMOD software and a 3-D digital mouse brain atlas. Postmor-
tem brain tissues from the same APPswe and wt mice in all
age groups were analysed for Aβ deposition and astrocytosis
by in vitro autoradiography using 3H-AZD2184, 3H-Pitts-
burgh compound B (PIB) and 3H-L-deprenyl and immuno-
staining performed with antibodies for Aβ42 and glial fibril-
lary acidic protein (GFAP) in sagittal brain sections.
Results 11C-AZD2184 PET retention in the cerebral cortices
of APPswe mice was significantly higher at 18–24 months
than in age-matched wt mice. Cortical and hippocampal 11C-
DED PET binding was significantly higher at 6 months than at
8–15 months or 18–24 months in APPswe mice, and it was
also higher than at 8–15 months in wt mice. In vitro autoradi-
ography 3H-AZD2184 and 3H-PIB binding confirmed the
in vivo findings with 11C-AZD2184 and demonstrated age-
dependent increases in Aβ deposition in APPswe cortex and
hippocampus. There were no significant differences between
APPswe and wt mice in 3H-L-deprenyl autoradiography bind-
ing across age groups. Immunohistochemical quantification
demonstrated more Aβ42 deposits in the cortex and hippo-
campus and more GFAP+ reactive astrocytes in the hippocam-
pus at 18–24 months than at 6 months in APPswe mice.
Conclusion The findings provide further in vivo evidence that
astrocytosis occurs early in AD, preceding Aβ plaque
deposition.
Keywords Alzheimer’s disease . APPswemice . Amyloid .
Astrocytosis . 11C-AZD2184 . 11C-Deuterium-L-deprenyl .
PET imaging
Introduction
Alzheimer’s disease (AD) is the most common neurodegener-
ative disease and dementia disorder. Beta-amyloid (Aβ)
plaques, neurofibrillary tangles, neuroinflammation and
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neuronal loss in the brain are pathological hallmarks of AD
that are thought to play a key role in the progressive decline in
episodic memory and cognition [1, 2]. Recent advancements
in molecular imaging using positron emission tomography
(PET) have allowed the visualization of fibrillar Aβ plaques
and the monitoring of disease progression in vivo in AD pa-
tients [3]. Amyloid tracers developed for human use include
11C-Pittsburgh compound B (11C-PIB) [4], 11C-BF-227 [5],
11C-AZD2184 [6], 18F-FDDNP [7], 18F-florbetapir [8], 18F-
flutemetamol [9], 18F-florbetaben [10] and 18F-AZD4694
[11]. Recently, 18F-florbetapir, 18F-flutemetamol and 18F-
florbetaben have been approved by the European Medicines
Agency (EMA) and by the US Food and Drug Administration
(FDA) to visualize amyloid plaques. We recently reported that
florbetaben, PIB and florbetapir all bind to a high-affinity
binding site in postmortem AD brain tissues [12], demonstrat-
ing their reliability for detecting fibrillar Aβ deposits. Longi-
tudinal amyloid PET imaging in large at-risk and patient pop-
ulations has shown that it takes≈20 years for build-up of path-
ological amyloid plaque load in the brain [13].
Neuroinflammation is increasingly recognized to play an
early role in AD [14–16]. Studies in postmortem AD brains
have demonstrated abundant reactive astrocytes and microglia
around amyloid plaques [17], but little is known about their
in vivo distribution or function. PET imaging of astrocytosis
in subjects with mild cognitive impairment (MCI) and in AD
patients using 11C-deuterium-L-deprenyl (11C-DED) has sug-
gested that astrocytosis occurs early in AD [18].
A wide range of transgenic mice harbouring familial
AD mutations that model different aspects of AD patho-
genesis are currently available. Although none of these
fully replicates the disease, they have provided important
insights into the pathophysiology of Aβ toxicity. The de-
velopment of pathology varies among the mouse strains.
APPswe mice carrying the APP Swedish mutation devel-
op amyloid pathology more slowly than APP/PS1 and
APP23 mice [19].
In this study, we investigated the time course of
astrocytosis and amyloid plaque deposition by multitracer
in vivo microPET imaging in APPswe mice aged 6–24
months. The postmortem brains were then analysed using cor-
relative immunohistochemistry and autoradiography.
Materials and methods
Animals
Male and female transgenic mice expressing the APP Swedish
mutation (Tg2576) were obtained by in-house breeding at the
Karolinska Institutet animal care facility, as previously de-
scribed [20]. Wild-type (wt) littermates served as controls.
All mice were housed under the same conditions with access
to food and water ad libitum and a 12-h light/dark cycle. All
experimental procedures complied with the guidelines and
regulations of the Swedish National Board for Laboratory
Animals, and the Regional Ethics and Animal Research Com-
mittee at Karolinska Institutet approved the study protocol.
PET imaging in APPswe and wt mice
A nanoScan® small animal PET/magnetic resonance imaging
(PET/MRI) and a PET/computed tomography (PET/CT)
scanner system (Mediso Ltd, Budapest, Hungary) [21, 22]
were used to image the brains of 6-, 8- to 15- and 18- to 24-
month-old APPswe mice (n=4–6 animals in each age group)
and 8- to 15- and 18- to 24-month-old wt mice (n=3–6 ani-
mals in each age group) at the Karolinska Experimental Re-
search and Imaging Centre (KERIC). The PET radiotracers
11C-AZD2184 and 11C-DED were synthesized at Karolinska
PET Radiochemistry Laboratory in a similar way as reported
elsewhere [23, 24], with a radiochemical purity >98 % and
specific radioactivity of 181±211 and 373±443 (mean±SD)
GBq/μmol, respectively. The mice were anaesthetized with
1.5 % (v/v) isoflurane and each mouse underwent an MRI or
CT scan for anatomical reference. 11C-AZD2184 (10.6±
1.8 MBq) and 11C-DED (10.5±1.6 MBq) were administered
by venous tail injections and dynamic PET scans were ac-
quired over 63 min in 3-D list mode. The injected mass was
0.020±0.014 μg (11C-AZD2184) and 0.028±0.037 μg (11C-
DED); the corresponding injected quantities expressed in
nanomolar units were 0.098±0.051 nmol (11C-AZD2184)
and 0.174±0.242 nmol (11C-DED). Most mice had PET scans
with both tracers, with a 6- to 15-day interval between scans.
PET image data reconstruction and processing
The PET data were corrected for decay and dead time. The
image reconstruction protocol consisted of a 400–600 keV
energy window with a 5 ns time window, using a 20-
iteration maximum likelihood expectation maximization
(MLEM) algorithm and a 1×10−4 regularization parameter.
The PET data were reconstructed into 25 time frames: 4×10,
4×20, 4×60, 7×180 and 6×360 s, with an isovoxel of
0.3 mm. PMOD v3.3 software (PMOD Technologies Ltd,
Zurich, Switzerland) was used for the coregistration of the
PET images to a 3-D digital T2-weighted MRI mouse brain
template incorporated in PMOD. To facilitate the
coregistration of dynamic PET data, two separate averaged
PET images, i.e. the integrated early (0–4 min) and late (4–
63 min) frames, were obtained. The early frames were manu-
ally coregistered to the mouse brain template available in
PMOD for each mouse PET image. The corresponding trans-
formation matrix was subsequently applied to the averaged
late-frames PET image, and the manual coregistration was
further improved. The final transformation matrix was then
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applied to the whole dynamic PET sequence for each mouse,
resulting in PET images that were coregistered to the mouse
brain template in PMOD.
Quantification of PET tracer uptake
Coregistered PET images were analysed by region of interest
(ROI) analysis using a 3-D mouse brain atlas in PMOD. An
averaged 21- to 33-min frame was used for quantifying the
extent of 11C-AZD2184 and 11C-DED radiotracer uptake, and
the averaged activity in each target ROI was subsequently
corrected for injected radioactivity and weight of the mice
and expressed in standardized uptake value (SUV) units.
The cortex, bilateral hippocampus and cerebellum were se-
lected for further evaluation. Postmortem immunohistochem-
ical analysis of APPswemouse brains revealed the presence of
relatively few diffuse plaques in the cerebellum, which also
differed morphologically from those in the cortex and hippo-
campus. The cerebellum was thus not used as a reference for
quantifying 11C-AZD2184 retention. Astrocytes were more
sparse in the cerebellum than in the cortex and hippocampus,
and 11C-DED binding was quantified using a Simplified Ref-
erence Tissue Model (SRTM) in PMOD using the cerebellum
as a reference and expressed as non-displaceable binding po-
tential (BPND) for each ROI. In addition,
11C-DED was also
expressed by its semi-quantitative target to cerebellum ratio in
SUV ratio (SUVR) units for each ROI.
In vitro homogenate binding and autoradiography
in APPswe and wt mice postmortem brains
Within 2 weeks after undergoing one 11C-AZD2184 and one
11C-DED PET scan, each mouse was sacrificed by cervical
dislocation and its brain removed for postmortem analyses.
Right brain hemispheres were stored at –80 °C and used in
homogenate binding and autoradiography assays. Left brain
hemispheres were post-fixed with 4 % paraformaldehyde
(pH 7.4), transferred to a sucrose cryoprotectant for 24 h at
4 °C and then frozen at –80 °C for immunohistochemistry.
Binding assays with 3H-AZD2184 (specific activity
21.9 Ci/mmol, custom synthesized at Karolinska PET Radio-
chemistry Laboratory, Stockholm, Sweden), 3H-PIB (specific
activity 85 Ci/mmol) and 3H-L-deprenyl (specific activity
80 Ci/mmol, both custom synthesized by Quotient
Bioresearch, Cardiff, UK) were performed on cortical homog-
enates (50–100 μg tissue) from APPswe mice. Autoradiogra-
phy was performed by incubation of triplicate sagittal sections
(10 μm) from APPswe and wt mouse brains with 3 nM 3H-
AZD2184, 1.5 nM 3H-PIB and 10 nM 3H-L-deprenyl, accord-
ing to methods described previously [25, 26]. Adjacent sec-
tions were incubated with unlabelled 1 μM BTA-1 or
10 μM L-deprenyl (Sigma-Aldrich, St. Louis, MO, USA) to
determine non-specific binding. The autoradiograms were
analysed with Multigauge software V3.0 (Fuji, Tokyo, Japan)
and specific binding values were expressed as picomoles per
gram tissue. Selected ROIs were the cerebral cortex, the hip-
pocampus and the cerebellum.
Immunohistochemistry
APPswe and wt mice brain sections were immunostained with
mouse monoclonal Aβ42 (1:200; Signet Laboratories, Ded-
ham, MA, USA), and polyclonal rabbit glial fibrillary acidic
protein (GFAP) (1:500; DakoCytomation, Glostrup, Denmark)
antibody. Controls consisted of brain sections treated with ei-
ther non-immune serum or omission of the primary antibody.
Sections were imaged sequentially at ×10 and ×20 magnifica-
tion under light microscopy (Leica, Wetzlar, Germany) with an
attached image capture analysis system (ProgRes Capture Pro
2.8.8 software, JenOptik AG, Jena, Germany). Quantification
was performed using Image J software (National Institutes of
Health, Bethesda, MD, USA) and the results expressed as the
number of immunopositive cells per square millimetre.
Statistics
Statistical analyses of the in vivo PET data, in vitro binding
assays and postmortem immunohistochemistry analyses were
performed using SPSS (IBM SPSS Statistics, Version 22.0)
and GraphPad Prism version 5.0 software. Correlations be-
tween regional PET tracer uptake and age of mice were per-
formed by non-parametric Spearman’s rank-order correlation
method. Comparisons between the APPswe and wt mice ac-
cording to age group were performed by independent sample,
one- or two-tailed, non-parametric Mann-Whitney U tests.
Results were presented as mean ± SD for each study
group. Significant differences between groups were indicated
by *p<0.05, **p<0.01 and ***p<0.001.
Results
The demographics of 11C-AZD2184 and 11C-DED in vivo
PET-imaged APPswe and wt mice are shown in Table 1. Vi-
sual inspection of the PET time-activity curves (TACs) for
each ROI showed that both tracers were relatively homoge-
neously distributed throughout the brain. The uptake of both
tracers peaked rapidly at 30–40 s post-injection and they were
washed out relatively quickly so that the level of radioactivity
had dropped after about 4 min post-injection (Suppl. Fig. S1).
11C-AZD2184 PET retention in APPswe mice
Figure 1a displays average coronal images of 11C-AZD2184
PET scans in APPswe (aged 6, 8–15 and 18–24 months) and
wt (aged 8–15 and 18–24 months) mice, coregistered to a 3-D
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T2-weighted MRI mouse brain template. 11C-AZD2184 reten-
tion expressed in SUV units showed increasing Aβ plaque de-
position as a function of age in APPswe mice, with greater
retention at 18–24 months. 11C-AZD2184 PET retention was
significantly (67 %, p=0.04) greater in 18- to 24-month-old
APPswe mice cortices (mean SUV=0.119±0.053) than in
age-matched wt mice cortices (mean SUV=0.071±0.018)
(Fig. 1b). The comparison between 11C-AZD2184 retention in
18- to 24-month-old APPswe mice hippocampi (mean SUV=
0.108±0.052) and in age-matched wt mice hippocampi (mean
SUV=0.070±0.017) did not reach statistical significance (p=
0.12) (Fig. 1b). 11C-AZD2184 retention in a combined cortical
and hippocampal ROI was significantly higher in 18- to 24-
month-old APPswe compared to wt mice (p=0.05). The 11C-
AZD2184 retention in the cerebella of 18- to 24-month-old
APPswe mice (mean SUV=0.115±0.058) did not significantly
differ from that in age-matched wt mice (mean SUV=0.089±
0.027) (p=0.33). 11C-AZD2184 PET retention in the cortices,
hippocampi and cerebella of 8- to 15-month-old APPswe mice
did not differ significantly from that in 6-month-old APPswe or
8- to 15-month-old wt mice. Low 11C-AZD2184 brain retention
was observed in all wt mice, irrespective of age (Fig. 1a, b).
11C-DED PET binding in APPswe and wt mice
Figure 2a shows parametric BPND images of
11C-DED PET
illustrated by coronal sections coregistered to a 3-D T2-
weighted MRI mouse brain template for representative
APPswe and wt mice. 11C-DED binding showed a different
time course in APPswe compared to wt mice.
11C-DED binding was significantly greater in the cerebral
cortices of 6-month-old APPswe mice (BPND=0.083±0.045)
than in the 8- to 15-month-old cohort of wt mice (BPND=
0.018±0.005; p=0.014). 11C-DED binding was also signifi-
cantly greater in the hippocampi of 6-month-old APPswe
mice (BPND=0.140±0.030) than in the 8- to 15-month-old
cohort of wt mice (BPND=0.075±0.037; p=0.027) (Fig. 2b).
When comparing the three age groups of APPswe mice,
11C-DED binding was significantly higher in the cerebral cor-
tices and hippocampi at 6 months compared to either 8- to 15-
or 18- to 24-month-old APPswe mice. In the cerebral cortices,
the 11C-DED binding at 6 months was significantly higher than
at 8–15 months (BPND=0.028±0.020; p=0.033) and than at
18–24 months (BPND=0.027±0.013; p=0.019). In the hippo-
campi, the 11C-DED binding at 6 months was significantly
higher than at 8–15 months (BPND=0.081±0.023; p=0.019)
and than at 18–24 months (BPND=0.058±0.033; p=0.019).
11C-DED binding (BPND) was observed to decline with age
in APPswe mice in the cerebral cortices (Spearman’s rS=
−0.595; p=0.015) and in the hippocampi (Spearman’s rS=
−0.707; p=0.002), while BPND was not correlated with age
in wt mice in either the cortical or hippocampal regions.
When 11C-DED binding was evaluated in semi-quantitative
SUVR units, it was significantly greater in the cerebral cortices
of 6-month-old APPswe mice (SUVR=1.094±0.063) than in
the 8- to 15-month-old cohort of wt mice (SUVR=1.036±
0.036; p=0.05). There were no statistically significant differ-
ences in 11C-DEDwhen expressed in SUVR units for any other
comparison between groups of APPswe or wt mice in either the
cerebral cortices or the hippocampi.
3H-AZD2184 and 3H-PIB in vitro binding in postmortem
APPswe and wt mouse brain
Saturation binding studies with 3H-AZD2184 demonstrated the
presence of high-affinity binding sites (Kd 10.6 nM, Bmax 530
pmol/g tissue) in the cerebral cortices of APPswe mice. The
autoradiography binding profiles for 3H-AZD2184 in the
brains of 6- to 24-month-old APPswe mice and 8- to 24-
month-old wt mice are illustrated in Fig. 3a. More 3H-
AZD2184 binding sites were detected in APPswe mice at 18–
24months than in age-matchedwtmice; binding densities were
higher in the hippocampi (299.6±73.0 pmol/g tissue) and cere-
bral cortices (259.3±113.3 pmol/g tissue) than in the cerebella
(148.8±61.7 pmol/g tissue) in these APPswe mice (Fig. 3a, b).
Table 1 Demographics of
in vivo 11C-AZD2184 and 11C-
DED microPET studies

















APPswe 6 4 4/0 24.8±6.1 9.3±2.0 4 4/0 25.0±5.4 8.9±1.5
APPswe 8–15 6 6/0 29.7±3.3 10.4±2.0 6 6/0 33.2±4.9 11.1±1.6
APPswe 18–24 5 3/2 23.0±3.9 10.9±2.7 6 3/3 25.0±2.9 9.5±1.4
C57B6
(wt)
8–15 3 2/1 29.4±3.9 11.2±0.5 5 4/1 26.9±3.9 10.9±1.0
C57B6
(wt)
18–24 6 5/1 31.7±4.6 10.9±1.3 6 5/1 31.7±4.6 11.2±0.9
The mice weights and injected doses in the microPET studies are expressed as means±SD for each study group
PET positron emission tomography, M male, F female, Inj. injected, wt wild-type
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The number of 3H-AZD2184 binding sites in the cerebral
cortices and hippocampi of 18- to 24-month-old APPswe mice
was significantly greater than that in the 6-month-old (cortex
p=0.0424, hippocampus p=0.0061) and 8- to 15-month-old
(p=0.0007, p=0.0003) APPswe cohorts, respectively
(Fig. 3b). 3H-AZD2184 binding levels were twofold higher in
the cerebral cortices and the hippocampi of 18- to 24-month-
old APPswe mice than in age-matched wt mice (cortex p=
0.0025, hippocampus p=0.0025). There were no significant
differences in 3H-AZD2184 binding densities in the cerebellum
between APPswe and wt mice at any age (Fig. 3b).
The amyloid ligand 3H-PIB was also used to quantify brain
amyloid levels, and the profiles for 3H-PIB autoradiography
binding in the brains of 6- to 24-month-old APPswe mice and
8- to 24-month-old wt mice are displayed in Fig. 4a. Higher
levels of 3H-PIB binding were observed in 18- to 24-month-
old APPswe mice, with higher binding densities in the cere-
bral cortices (547.2±107.6 pmol/g tissue) and the hippocampi
(504.3±92.7 pmol/g tissue) and the lowest in the cerebella
(456.1±154.1 pmol/g tissue).
We found significantly higher levels of 3H-PIB binding in
the cerebral cortices and hippocampi of 18- to 24-month-old
APPswe mice (p=0.0121, p=0.0242) than in 6-month-old
APPswe mice and higher 3H-PIB binding in the hippocampi
of 18- to 24-month-old APPswe mice (p=0.0311) than in 8- to































6M 8-15M 18-24M 6M 8-15M 18-24M 6M 8-15M 18-24M
WT
*
Fig. 1 11C-AZD2184 microPET
imaging in APPswe and wild-
type (WT) mice. a 11C-AZD2184
microPET coronal images from
three age groups of APPswe mice
show greatest retention at 18–24
months (n=5) and low retention
in two groups of WT mice aged
8–15 months (n=3) and 18–
24 months (n=6). Coronal
images, depicted using a common
scale from 0.0 to 0.3 SUV units,
were obtained from averaged
dynamic 11C-AZD2184
microPET scans (4–39 min post-
injection for visualization
purposes), subsequently
combined into an average image
for each mouse age group, and
coregistered to a 3-D T2-
weighted MRI mouse brain
template using PMOD v3.3
software. Four coronal sections
are shown for each group (left to
right) at −5.2 mm, −3.2 mm,




scans (21–33 min post-injection)
expressed in SUV units for the
cortices, hippocampi and cerebel-
la from three groups of APPswe
mice aged 6 months (n=4), 8–
15 months (n=6) and 18–24
months (n=5) and two groups of
WT mice aged 8–15 months (n=
3) and 18–24 months (n=6).
Values in the columns are
expressed as means±SD.
Significant differences between
groups are indicated by *p<0.05
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significant differences in 3H-PIB binding levels in the cerebel-
lum between 18- to 24-month-old APPswe mice and age-
matched wt mice (Fig. 4b).
3H-L-deprenyl in vitro binding in postmortem APPswe
and wt mouse brain
3H-L-deprenyl saturation binding revealed the presence of
high-affinity binding sites in the cortices of 6-month-old (Kd
9.5 nM, Bmax 201 pmol/g tissue) and 20-month-old (Kd 16.0
nM, Bmax 238 pmol/g tissue) APPswe mice.
The autoradiography binding profiles for 3H-L-depre-
nyl in sagittal brain sections from 6- to 24-month-old
APPswe and 8- to 24-month-old wt mice are shown in
Fig. 5a. 3H-L-deprenyl demonstrated similar binding
levels in both the cortex and hippocampus across the
different age groups of APPswe mice that were compa-





























Fig. 2 11C-DED microPET
imaging in APPswe and wild-
type (WT) mice. a 11C-DED
microPET coronal images for
APPswe mice show a different
time course from that for WT
mice, where 11C-DED binding
was observed to decline with age
in APPswe mice but not in WT
mice. The coronal sections
correspond to parametric BPND
maps of 11C-DED PET smoothed
by a 0.5-mm Gaussian filter and
coregistered to a 3-D T2-weight-
ed MRI mouse brain template
using PMOD v3.3 software for
representative APPswe compared
to wt mice. All images are illus-
trated in a common scale from 0.0
to 0.4 units of BPND. Four coronal
sections are shown for each
mouse (left to right) at −5.2 mm,
−3.2 mm, −1.2 mm and +0.8 mm
from the bregma. b 11C-DED
binding in the cortex and
hippocampus, expressed as
BPND, obtained from SRTM of
11C-DED using the cerebellum as
a reference region, in three groups
of APPswe mice aged 6 months
(n=4), 8–15 months (n=6) and
18–24 months (n=6) and two
groups of WT mice aged 8–15
months (n=5) and 18–24 months
(n=6). Values in the columns are
expressed as means±SD.
Significant differences between
groups are indicated by *p<0.05
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Distribution of Aβ42 deposits and GFAP-immunoreactive
astrocytes in APPswe mice brains
Aβ42 immunostaining showed more Aβ42 deposits in the cor-
tices and hippocampi of 18- to 24-month-old APPswe mice
than in 6-month-old APPswe mice (Fig. 6a, b). Scarce diffuse
Aβ42 deposits were observed in the cortices and hippocampi of
6-month-old APPswe mice, whereas increased numbers of
both diffuse and cored Aβ42 plaque deposits were detected in
18- to 24-month-old APPswe mice (Fig. 6a, b). Diffuse Aβ42
deposits were also detected in the cerebella of APPswe mice at
18–24 months of age, but these were morphologically different
from those observed in the cortices and hippocampi, and were
mainly distributed along blood vessels and meninges (Fig. 6a).
No Aβ42 aggregates were observed in the cortex and hippo-
campus of the 8-month-old and 20-month-old wt mice (Fig 6a).
GFAP+ astrocytes were significantly more abundant in the
hippocampi of APPswe mice at 18–24 months than at
6 months, while the difference was not statistically significant
in the cortex (Fig. 6c). Age-dependent changes in the mor-
phology and phenotype of GFAP+ reactive astrocytes were
also observed. In the cortices and hippocampi of 6-month-
old APPswe mice, in the absence of extracellular Aβ42
plaques, the majority of GFAP+ reactive astrocytes were
atrophic and a large proportion of these contained cyto-


































aFig. 3 3H-AZD2184 in vitro
binding in postmortem brains
fromAPPswe and wild-type (WT)
mice. a Representative 3H-
AZD2184 (3 nM) autoradiograms
in sagittal brain sections from
APPswe (6, 11 and 23 months)
andWT (11 and 18months) mice.
b 3H-AZD2184 binding (3 nM) in
the cortices, hippocampi and
cerebella of brains from APPswe
mice aged 6 months (n=4), 8–15
months (n=9) and 18–24 months
(n=7) and WT mice aged 8–15
months (n=5) and 18–24 months
(n=5). Values in the columns are
expressed as means±SD.
Significant differences between
groups are indicated by *p<0.05,
**p<0.01 and ***p<0.001
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of 18- to 24-month-old APPswe mice, both atrophic and
hypertrophic GFAP+ reactive astrocytes were detected,
with only a few of these containing cytoplasmic Aβ42.
The hypertrophic astrocytes in the cortices and hippo-
campi of 18- to 24-month-old APPswe mice accounted
for about 10 % of the total reactive astrocytes and were
found surrounding Aβ42-stained amyloid plaques, while
the atrophic astrocytes were observed distant from the
Aβ42 amyloid plaques. GFAP
+ reactive astrocytes were
lower in the cortex and hippocampus of wt mice com-
pared to APPswe mice at both 8 months of age and 18–
24 months of age (Fig 6a, c).
Discussion
The use of multitracer PET imaging in an AD transgenic
mouse model to investigate the evolution of and relationships
between astrocytosis and amyloid plaque deposition in early
AD has, to our knowledge, not been described before, as in-
dicated also in a recent review [27]. Previous amyloid PET
studies in AD transgenic mice have reported various findings
[27]. For example, retention of 11C-PIB was no greater in the
brains of 12-month-old APP/PS1 mice than in wt mice in one
study [28], while subsequent studies reported increased 11C-PIB
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Fig. 4 3H-PIB in vitro binding in
postmortem brains from APPswe
and wild-type (WT) mice. a
Representative 3H-PIB (1.5 nM)
autoradiograms in sagittal brain
sections from APPswe (6, 11 and
23 months) and WT (11 and 18
months) mice. b 3H-PIB binding
(1.5 nM) in the cortices,
hippocampi and cerebella of
brains from APPswe mice aged 6
months (n=4), 8–15 months (n=
9) and 18–24 months (n=8) and
WT mice aged 8–15 months (n=
5) and 18–24 mths (n=5). Values
are expressed as means±SD.
Significant differences between
groups are indicated by *p<0.05
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in 22-month-old APPswe mice [30, 31]. Other similar studies in
APP/PS1mice showed increased retention at 9 months [32] and
no difference at 15–22 months compared to age-matched wt
mice [30]. Increased PET retention of 18F-florbetaben in 16-
month-old APPswe mice [33] and 18F-florbetapir in 5-month-
old APP/PS1 mice [34] has been reported.
In this study, we used PET imaging to detect increased 11C-
AZD2184 retention in older APPswe mice. These in vivo
studies showed a significant increase in retention in the corti-
ces of 18- to 24-month-old APPswe mice versus age-matched
wt mice, and a similar increase in both the cortex and the
hippocampus was observed postmortem with 3H-AZD2184
and 3H-PIB in vitro autoradiography. Age-related increases
in 3H-AZD2184 binding densities, as well as with 3H-PIB,
and Aβ42 immunopositive deposits were also observed in
the cortices and hippocampi of APPswe mice, in agreement
with previously published findings of Aβ deposition in post-
mortem immunohistochemical studies in this model [35].
The gene expression and cellular morphology of reactive
astrocytes are highly heterogeneous across different brain re-
gions in both healthy and neurodegenerative- diseased brains
[36, 37]. Studies in AD transgenic mice have reported wide-
spread astroglial atrophy in the brain in the earlier stages of
AD prior to Aβ plaque deposition [38–40], but have also
indicated the presence of hypertrophic astrocytes surrounding
amyloid plaques [41]. The Aβ aggregates in the brain increase
the number of reactive astrocytes and/or phenotypic changes



































Fig. 5 3H-L-deprenyl in vitro
binding in postmortem APPswe
and wild-type (WT) mouse brain.
a Representative 3H-L-deprenyl
(10 nM) autoradiograms in
sagittal brain sections from
APPswe (6, 11 and 23 months)
andWTmice (11 and 18months).
b 3H-L-deprenyl (10 nM) in the
cortices, hippocampi and
cerebella of brains from APPswe
mice aged 6 months (n=4), 8–15
months (n=9) and 18–24 months
(n=7) and WT mice aged 8–15
months (n=5) and 18–24 months
(n=5). Values are expressed as
means±SD
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Our 11C-DED PET imaging findings demonstrated different
time courses for astrocytosis in APPswe andwtmice; 11C-DED
binding significantly decreased with age in APPswe mice in
cortex and hippocampus, while it was not correlatedwith age in
wt mice. 11C-DED binding was also significantly higher in the
cortices and hippocampi of 6-month-old APPswe mice com-
pared to other age groups of APPswe and compared to 8- to 15-
month-old wt mice. These findings and the observed absence
of Aβ plaques in 6-month-old APPswe mice indicate that
astrocytosis occurs prior to Aβ plaque deposition.
Previous studies have measured reactive astrocytes using
3H-L-deprenyl in vitro in AD postmortem brain tissue [26, 44,
45] and 11C-DED in vivo [18, 46]. Interestingly, early 11C-DED
PET binding was observed in prodromal AD patients [18],
Fig. 6 Immunohistochemical
staining in APPswe mice. a
Representative
immunohistochemical staining of
Aβ aggregates and GFAP+
reactive astrocytes in the cortex,
hippocampus (dentate gyrus) and
cerebellum of one 6-month-old
and one 20-month-old APPswe
mouse (×20), scale bars=
0.25 mm, and one 8-month-old
and one 20-month-old wild-type
(WT) mouse (×10), scale bars=
0.5 mm; GFAP+ astrocytes
(brown) surround Aβ42 positive
plaques (red). b Higher levels of
Aβ42 in the cortices and
hippocampi of 18- to 24-month-
old APPswe mice (n=4) than in
those of 6-month-old APPswe
mice (n=4). No Aβ42 aggregates
were observed in the cortex and
hippocampus of the 8-month-old
and 20-month-old WT mice. c
Higher levels of GFAP in the
hippocampi (dentate gyri) of 18-
to 24-month-old APPswe mice
(n=4) than in those of 6-month-
old APPswe mice (n=4). GFAP
levels of age-matched WT mice
are included for comparison.
Values are expressed as means±
SEM. Significant differences
between groups are indicated by
*p<0.05
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consistent with our results in APPswe mice. Astrocytosis as
measured by 11C-DED PETwas also observed to be negatively
correlated with grey matter density in the parahippocampus at
early prodromal AD stages [47]. Early 11C-DED PET binding
has also been reported in presymptomatic carriers of autosomal
dominant AD mutations several decades before onset of symp-
toms and earlier than Aβ deposition [48]. Therefore, our find-
ings of early 11C-DED PET binding in APPswe mice before
Aβ deposition are consistent with reported in vivo PET find-
ings in humans, highlighting the translational aspects of this
study.
In contrast to the in vivo 11C-DED PET binding results,
there were no significant differences between APPswe and wt
mice in the in vitro 3H-L-deprenyl autoradiography results.
Possible explanations for this include either a reduction in
monoamine oxidase B (MAOB) enzyme activity when mea-
sured in vitro compared to in vivo [46] or technical limitations
due to a reduced in vitro enzyme activity in transgenic
APPswe mice compared to humans.
The level of GFAP upregulation in astrocytes has been
reported to be dependent on both the brain region and the
context, which could in part underlie the heterogeneity of
functions mediated by astrocytes in the central nervous
system, evidenced by their diverse neuroprotective or
neurotoxic functions across different stages in AD [49].
Our immunostaining results in APPswe mice revealed
more GFAP reactive astrocytes in the cortices and hippo-
campi of 18- to 24-month-old than of 6-month-old
APPswe mice, although the age-dependent increase was
significant only in the hippocampus. There is increasing
evidence that GFAP is not expressed uniformly by all
astrocytes [50] and that different GFAP isoforms develop
in response to plaque-related gliosis, as shown in APP/
PS1 and 3xTg AD transgenic mice [51]. It has been re-
ported [52] that about 80 % of the astrocytes in the hip-
pocampus express GFAP, compared to only 15–20 % of
those in the cortex, which could at least partially explain
our immunohistochemical results showing a significant
increase in GFAP with age in the hippocampus. Other
studies in AD transgenic mice have reported GFAP ex-
pression prior to Aβ plaque deposition [53] and also as an
age-dependent process that is correlated with oligomeric
Aβ but not with plaque burden [54]. GFAP expression in
astrocytes has also been reported as a late event related to
plaque formation and maturation, and as a neuroprotective
event that limits Aβ plaque growth [55].
In our present study, in contrast to the early increase in 11C-
DED binding in the APPswe mouse brain cortex, GFAP im-
munoreactivity was predominantly a late event. There was a
significant age-dependent increase in the number of GFAP+
reactive astrocytes in the hippocampus, possibly indicating the
presence of distinct subpopulations of astrocytes and/or dif-
ferent stages of reactive astrocytosis. The different time course
of increases in 11C-DED binding and GFAP upregulation ob-
served in APPswe mice is consistent with findings in human
AD. Quantitative autoradiography studies in postmortem AD
brains have shown a strong regional correlation between the
number of GFAP+ reactive astrocytes and the extent of in vivo
11C-PIB and in vitro 3H-PIB binding, but there appears to be
no regional correlation between postmortem 3H-L-deprenyl
and in vivo 11C-PIB binding [45]. The regional and laminar
distribution patterns of 3H-L-deprenyl reactive astrocytes also
differed from those of fibrillar Aβ in AD autopsy brains [26].
Thus, our observation of early 11C-DED binding in the corti-
ces of APPswe mice might reflect the presence of a subset of
activated astrocytes that is functionally different from those
measured by GFAP at later stages.
The small, soluble Aβ forms that have been observed in
APPswe mice from birth [56, 20] could influence astrocyte
function. For example, Aβ25–35 peptides caused overexpres-
sion of MAOB in cultured rat astrocytes [57]. Further, MAOB
overexpression in astrocytes led to production of proinflamma-
tory molecules contributing to exacerbated neuroinflammation
and Aβ plaque formation at later stages [58]. Our observation
of early elevated 11C-DED binding might thus reflect a reaction
of astrocytes to these small Aβ forms, with potential beneficial
and/or neurotoxic consequences. Activated astrocytes appear to
play a role in the clearance of Aβ [59, 60].Whether the reactive
astrocytes that were observed early in the development of AD,
as measured by elevated 11C-DED binding, have a phagocytic
function requires further investigation.
One limitation of this study was the limited spatial resolu-
tion of small animal PET imaging relative to the mouse brain
regions selected for quantification, which contained some thin
shapes being susceptible to partial volume effects. This might
account for the lower sensitivity of our in vivo versus in vitro
images. Inevitably, transgenic AD mice are an inherently lim-
ited model for human disease and APPswe mice might phe-
notypically reflect only some aspects of AD [19]. Astrocytosis
was elevated at 6 months and it subsequently declined with
age in APPswe mice, consistent with findings of increased
astrocytosis in the prodromal phase of AD followed by de-
creases in later stages in humans [18]. The cross-sectional
design of this study allowed a parallel in vivo/in vitro com-
parison of the regional and temporal distributions of Aβ de-
position and astrocytosis in the sameAPPswe and wt mice at a
given age interval. Further multitracer longitudinal PET imag-
ing studies in AD transgenic animal models could provide
additional insights into the temporal evolution of neuropatho-
logical changes during AD progression and could be useful
for testing new therapies targeting astrocytes, especially at the
earliest stages.
In conclusion, we provide in vivo evidence that
astrocytosis occurs early in AD and precedes Aβ plaque de-
position. The increasing recognition of heterogeneous and
context-dependent astrocytosis in the progression of AD
Eur J Nucl Med Mol Imaging (2015) 42:1119–1132 1129
indicates that more research is needed to elucidate the func-
tions of the different astrocyte populations in the brain at dif-
ferent stages of the disease.
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